Nyxoah Shares Hit Record Low at €3.34, Down 64% Over the Year
This Wednesday, Nyxoah recorded a new all-time low at €3.34, surpassing the previous record low set the day before. However, the stock of the Belgian medtech company specializing in sleep apnea treatment traded up 2.68% at €3.45 by late morning, after this unprecedented low. The upcoming publication of the 2025 annual results, scheduled for March 19, is the next major event for the stock.
Historic Low for Nyxoah Shares
During the session, Nyxoah's share price reached an all-time low of €3.34, surpassing the previous low from March 3. This new record highlights the extent of the deterioration suffered by the stock, which has lost 64.14% over the year and is down another 14.5% over the last three months. The slight recovery in the late morning, which brought the share price back to €3.45, occurred right at the technical support threshold of €3.36, a level that has so far acted as a temporary rebound zone. Technically, the RSI is at 27, indicating a pronounced oversold condition. This indicator, which measures the speed and intensity of price movements, suggests that selling pressure has reached an extreme level, which may favor technical recoveries in the short term without necessarily reversing the underlying trend. The 50-day moving average, at €4.04, remains well above the current price, confirming the dominant bearish orientation.
Financial Calendar and Upcoming Events for Nyxoah
Nyxoah's financial calendar schedules the publication of the 2025 annual results for March 19, just over two weeks away. This event represents a crucial deadline for the company based in Mont-Saint-Guibert, which operates in the highly capital-intensive segment of medical devices for obstructive sleep apnea. The annual accounts will allow for an assessment of commercial progress and cash consumption by the medtech, two parameters closely monitored by the market for this type of profile. Beyond this date, the calendar includes the results of the first quarter of 2026 on May 12, followed by the general meeting scheduled for June 10. The upcoming sequence of publications will provide increased visibility on the company's operational trajectory, in a context where the stock has seen its valuation shrink by two-thirds over the past twelve months. The beta of 0.29 also indicates that the stock operates relatively independently of major indices, with its dynamics primarily driven by factors specific to the company.
